Akero Therapeutics, Inc. Research and Development Expense
Akero Therapeutics, Inc. reported Research and Development Expense of $78.88 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-11-07
- Akero Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $78.88M, a 9.21% increase year-over-year.
- Akero Therapeutics, Inc. research and development expense for the quarter ending 2025-06-30 was $69.25M, a 25.18% increase year-over-year.
- Akero Therapeutics, Inc. research and development expense for the quarter ending 2025-03-31 was $69.57M, a 37.35% increase year-over-year.
- Akero Therapeutics, Inc. research and development expense for the quarter ending 2024-12-31 was $69.29M, a 29.78% increase year-over-year.
- Akero Therapeutics, Inc. research and development expense for fiscal 2024 was $247.50M, a 74.54% increase from fiscal 2023.
- Akero Therapeutics, Inc. research and development expense for fiscal 2023 was $141.80M, a 66.27% increase from fiscal 2022.
- Akero Therapeutics, Inc. research and development expense for fiscal 2022 was $85.28M, a 4.31% increase from fiscal 2021.
- Akero Therapeutics, Inc. research and development expense for fiscal 2021 was $81.76M, a 25.95% increase from fiscal 2020.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $78.88M 10-Q · filed 2025-11-07 | $148.14M derived: sum of 2 quarters · filed 2025-11-07 | $217.70M 10-Q · filed 2025-11-07 | $287.00M derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-06-30 | $69.25M 10-Q · filed 2025-08-08 | $138.82M 10-Q · filed 2025-08-08 | $208.11M derived: sum of 3 quarters · filed 2025-08-08 | $280.35M derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-03-31 | $69.57M 10-Q · filed 2025-05-12 | $138.86M derived: sum of 2 quarters · filed 2025-05-12 | $211.09M derived: sum of 3 quarters · filed 2025-11-07 | $266.41M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-12-31 | $69.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $141.53M derived: sum of 2 quarters · filed 2025-11-07 | $196.85M derived: sum of 3 quarters · filed 2025-11-07 | $247.50M 10-K · filed 2025-02-28 |
| 2024-09-30 | $72.23M 10-Q · filed 2025-11-07 | $127.55M derived: sum of 2 quarters · filed 2025-11-07 | $178.20M 10-Q · filed 2025-11-07 | $231.60M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $55.32M 10-Q · filed 2025-08-08 | $105.97M 10-Q · filed 2025-08-08 | $159.36M derived: sum of 3 quarters · filed 2025-08-08 | $198.00M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $50.65M 10-Q · filed 2025-05-12 | $104.04M derived: sum of 2 quarters · filed 2025-05-12 | $142.68M derived: sum of 3 quarters · filed 2025-05-12 | $170.66M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $53.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $92.03M derived: sum of 2 quarters · filed 2025-02-28 | $120.01M derived: sum of 3 quarters · filed 2025-02-28 | $141.80M 10-K · filed 2025-02-28 |
| 2023-09-30 | $38.63M 10-Q · filed 2024-11-08 | $66.62M derived: sum of 2 quarters · filed 2024-11-08 | $88.41M 10-Q · filed 2024-11-08 | $106.73M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $27.98M 10-Q · filed 2024-08-09 | $49.77M 10-Q · filed 2024-08-09 | $68.09M derived: sum of 3 quarters · filed 2025-02-28 | $93.18M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $21.79M 10-Q · filed 2024-05-10 | $40.11M derived: sum of 2 quarters · filed 2025-02-28 | $65.19M derived: sum of 3 quarters · filed 2025-02-28 | $86.56M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $18.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $43.41M derived: sum of 2 quarters · filed 2025-02-28 | $64.77M derived: sum of 3 quarters · filed 2025-02-28 | $85.28M 10-K · filed 2025-02-28 |
| 2022-09-30 | $25.09M 10-Q · filed 2023-11-13 | $46.45M derived: sum of 2 quarters · filed 2023-11-13 | $66.96M 10-Q · filed 2023-11-13 | $94.67M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $21.36M 10-Q · filed 2023-08-11 | $41.88M 10-Q · filed 2023-08-11 | $69.59M derived: sum of 3 quarters · filed 2024-02-29 | $89.06M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $20.51M 10-Q · filed 2023-05-15 | $48.23M derived: sum of 2 quarters · filed 2024-02-29 | $67.69M derived: sum of 3 quarters · filed 2024-02-29 | $91.67M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $27.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $47.18M derived: sum of 2 quarters · filed 2024-02-29 | $71.16M derived: sum of 3 quarters · filed 2024-02-29 | $81.76M 10-K · filed 2024-02-29 |
| 2021-09-30 | $19.47M 10-Q · filed 2022-11-04 | $43.45M derived: sum of 2 quarters · filed 2022-11-04 | $54.05M 10-Q · filed 2022-11-04 | $79.76M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $23.98M 10-Q · filed 2022-08-05 | $34.58M 10-Q · filed 2022-08-05 | $60.29M derived: sum of 3 quarters · filed 2022-08-05 | $77.67M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $10.60M 10-Q · filed 2022-05-06 | $36.31M derived: sum of 2 quarters · filed 2022-05-06 | $53.69M derived: sum of 3 quarters · filed 2022-05-06 | $66.73M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $25.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $43.09M derived: sum of 2 quarters · filed 2022-02-25 | $56.13M derived: sum of 3 quarters · filed 2022-02-25 | $64.92M 10-K · filed 2022-02-25 |
| 2020-09-30 | $17.38M 10-Q · filed 2021-11-12 | $30.42M derived: sum of 2 quarters · filed 2021-11-12 | $39.21M 10-Q · filed 2021-11-12 | $52.34M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $13.04M 10-Q · filed 2021-08-13 | $21.83M 10-Q · filed 2021-08-13 | $34.97M derived: sum of 3 quarters · filed 2022-02-25 | $48.85M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $8.79M 10-Q · filed 2021-05-13 | $21.93M derived: sum of 2 quarters · filed 2022-02-25 | $35.81M derived: sum of 3 quarters · filed 2022-02-25 | $41.77M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $13.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $27.02M derived: sum of 2 quarters · filed 2022-02-25 | $32.98M derived: sum of 3 quarters · filed 2022-02-25 | $37.05M 10-K · filed 2022-02-25 |
| 2019-09-30 | $13.88M 10-Q · filed 2020-11-12 | $19.84M derived: sum of 2 quarters · filed 2020-11-12 | $23.91M 10-Q · filed 2020-11-12 | $25.89M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $5.96M 10-Q · filed 2020-08-12 | $10.02M 10-Q · filed 2020-08-12 | $12.01M derived: sum of 3 quarters · filed 2020-08-12 | $13.26M derived: sum of 4 quarters · filed 2020-08-12 |
| 2019-03-31 | $4.06M 10-Q · filed 2020-05-13 | $6.05M derived: sum of 2 quarters · filed 2020-05-13 | $7.30M derived: sum of 3 quarters · filed 2020-05-13 | $15.72M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $3.24M derived: sum of 2 quarters · filed 2020-03-16 | $11.66M derived: sum of 3 quarters · filed 2020-03-16 | $11.88M 10-K · filed 2020-03-16 |
| 2018-09-30 | $1.25M 10-Q · filed 2019-11-12 | $9.67M derived: sum of 2 quarters · filed 2019-11-12 | $9.90M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $8.42M 10-Q · filed 2019-08-12 | $8.65M 10-Q · filed 2019-08-12 |